Danish insulin maker
Danish insulin maker Novo Nordisk A/S NVO, +3.03% said passenger lift will invest $2 billion over the next five years in new production facilities in the U.S. and Denmark to meet increasing global demand for diabetes medicines.
The company estimates 700 new production and engineering jobs will be created at the Clayton, North Carolina site, where it already employs over 700. The new facilities will produce ingredients for Novo Nordisk's current and furture range of pharmaceuticals.
In Malov, Denmark, the new site will provide tableting and packaging of oral products, with 100 new jobs created.The final design and cost of the new facilities will be presented in 2016 and are expected to be operational during 2020.